NCT00215449
Completed
Phase 3
Study in Patients With COPD
Dey1 site in 1 country690 target enrollmentSeptember 22, 2005
ConditionsCOPD
DrugsFormoterol Fumarate
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- COPD
- Sponsor
- Dey
- Enrollment
- 690
- Locations
- 1
- Primary Endpoint
- Measure of lung function
- Status
- Completed
- Last Updated
- 15 years ago
Overview
Brief Summary
The purpose of this study is to determine the efficacy and safety of the investigational drug in the treatment of COPD in comparison with a placebo.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Medical diagnosis of COPD
- •Current or prior history of cigarette smoking
Exclusion Criteria
- •Medical diagnosis of asthma
- •Chest x-ray (CXR) prior to Day 1 diagnostic of significant disease other than COPD
- •Significant condition or disease other than COPD
Outcomes
Primary Outcomes
Measure of lung function
Secondary Outcomes
- Change in lung function, as well as vital signs
- Physical Exam results, Adverse Event reporting, etc
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 2
Study in Patients With COPDCOPDNCT00215384Dey35
Completed
Phase 2
Study in Patients With COPDCOPDChronic Obstructive Pulmonary DiseaseNCT00215423Dey49
Completed
Phase 2
A Study to Evaluate Safety and Efficacy of BOTOX in Adults With Moderate COPDCOPDNCT06003049RMW Testing40
Completed
Not Applicable
Pharmaceutical Care for Chronic Obstructive Pulmonary Disease (COPD) Study.Chronic Obstructive Pulmonary Disease (COPD)NCT01260389University Hospital, Ghent734
Completed
Phase 2
A Study To Investigate The Effects Of GW856553 On Patients With COPD (Chronic Obstructive Pulmonary Disease)Pulmonary Disease, Chronic ObstructiveChronic Obstructive Pulmonary Disease (COPD)NCT00392587GlaxoSmithKline30